Surmodics, Inc. (NASDAQ:SRDX) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. cut its stake in Surmodics, Inc. (NASDAQ:SRDX) by 4.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 121,753 shares of the company’s stock after selling 6,212 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.85% of Surmodics worth $3,572,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of SRDX. Vanguard Group Inc. increased its position in Surmodics by 2.4% during the third quarter. Vanguard Group Inc. now owns 846,164 shares of the company’s stock worth $27,153,000 after purchasing an additional 19,635 shares during the last quarter. SG Americas Securities LLC acquired a new position in Surmodics in the fourth quarter valued at approximately $163,000. Strs Ohio increased its stake in Surmodics by 97.2% during the fourth quarter. Strs Ohio now owns 7,100 shares of the company’s stock worth $258,000 after acquiring an additional 3,500 shares during the last quarter. Russell Investments Group Ltd. raised its position in Surmodics by 6.4% in the fourth quarter. Russell Investments Group Ltd. now owns 67,845 shares of the company’s stock valued at $2,466,000 after purchasing an additional 4,066 shares during the period. Finally, Summit Global Investments purchased a new stake in Surmodics in the fourth quarter valued at $360,000. Hedge funds and other institutional investors own 96.63% of the company’s stock.

Surmodics Stock Down 0.2 %

NASDAQ:SRDX traded down $0.07 during mid-day trading on Wednesday, hitting $41.43. The stock had a trading volume of 143,013 shares, compared to its average volume of 197,149. Surmodics, Inc. has a twelve month low of $25.17 and a twelve month high of $42.44. The stock has a 50-day simple moving average of $41.20 and a two-hundred day simple moving average of $34.36. The company has a current ratio of 4.39, a quick ratio of 3.59 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $590.79 million, a PE ratio of 43.68 and a beta of 1.18.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.43. The business had revenue of $31.96 million during the quarter, compared to analysts’ expectations of $28.79 million. Surmodics had a net margin of 9.44% and a return on equity of 13.30%. During the same period in the previous year, the company earned ($0.40) EPS. On average, equities research analysts anticipate that Surmodics, Inc. will post -0.51 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on SRDX shares. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a research report on Wednesday, May 29th. Barrington Research reiterated a “market perform” rating on shares of Surmodics in a report on Thursday, May 30th. StockNews.com started coverage on Surmodics in a research report on Friday, July 26th. They issued a “hold” rating on the stock. Sidoti reissued a “neutral” rating and set a $43.00 price target on shares of Surmodics in a research report on Wednesday, May 29th. Finally, Lake Street Capital restated a “hold” rating and issued a $43.00 price objective on shares of Surmodics in a report on Wednesday, May 29th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $50.00.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).